Contineum Therapeutics, Inc. Class A
(NASDAQ: CTNM)
Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA.
10.945
-0.035
(-0.32%)
Range
10.910 - 11.035
(1.15%)
Open
11.020
Previous Close
10.980
Bid Price
-
Bid Volume
-
Ask Price
-
Ask Volume
-
Volume
4,204
Value
-
Remark
Delayed prices. Updated at 06 Dec 2025 00:06.
Data powered by
View All Events
Loading Chart...
Please login to view stock data and analysis
